Advancing GLP-1 Drug Developments with Integrated Solutions

At Pharmapack 2025 in Paris, Audrey Chardonnet from Aptar Pharma discussed the growth of GLP-1 drugs for treating metabolic diseases like diabetes and obesity. She emphasized the effectivess of these drugs in managing blood sugar levels and promoting weight loss, as well as the importance of drug delivery systems in improving patient compliance and treatment outcomes. Audrey Chardonnet highlighted the contributions of major pharmaceutical companies and discussed the continued market growth that is expected in the coming years, driven by the emergence of new players and the approval of GLP-1 drugs for treating an increasing array of diseases. 

Audrey explained how Aptar Pharma continues to evolve its offerings to meet the needs of the GLP-1 market, both in terms of volume and quality of drug delivery components. She placed special emphasis on Aptar Pharma’s complete range of Rigid Needle Shields, featuring type 1 rubbers and designs to accommodate various needle sizes while supporting autoinjector integration. She also discussed how Advanced Parenteral Closure Solutions can accelerate GLP-1 drug development, including PremiumCoat® ETFE film-coated pre-filled syringe plungers and vial stoppers, PremiumFill® solutions for improved specification on particulate contamination, and RTU (Ready-to-Use) gamma sterilized components with guarantee of sterility at the time of use.  

In addition to discussing syringe plungers and Rigid Needle Shields, Audrey covered Aptar Pharma’s expansion program, explaining how it will bring extra capacity to support the growth of the market. In addition to capacity, Aptar Pharma’s expansion is driven by quality and innovation, leveraging clean rooms and advanced robotics, raising the standards of manufacturing to meet the expectations of GLP-1 drug manufacturers. 

Furthermore, Audrey presented Aptar Pharma’s services capabilities for supporting drug development from formulation to patient. Gateway Analytical’s expertise helps drug developers accelerate their early-stage development through a range of analytical services such as extractable and leachable studies or particulate analysis. When developing chronic medications such as GLP-1 drugs, Audrey focused on the importance of treatment adherence for therapeutic success and explained how Noble’s patient service could help onboard patients on how to use their autoinjector or pen injector confidently and reliably. 

Audrey closed the presentation by highlighting sustainability as a strategic pillar for the future of Aptar Pharma’s collaboration with the pharmaceutical industry. In addition to reinforcing Aptar Pharma’s commitment to making its manufacturing and products more sustainable, she explained how the Injectable division has already implemented large-scale upgrades of its facilities to reduce energy consumption and waste generation. 

In summary, this presentation at Pharmapack 2025 underlined Aptar Pharma’s commitment to supporting the growth of the GLP-1 market by delivering high quality injectables components, expanding manufacturing capacity and focusing on improving patient outcomes. Key takeaways include Aptar Pharma’s comprehensive approach, from formulation to patient, positions the company as a valuable player in driving advancements in the pharmaceutical industry.